Table 3

Sensitivity analyses*

Subgroup

Study arm

Clinical success

Microbiologic eradication

Resistance at baseline

Emergent resistance


PA isolates (n)

% (range)

PA isolates (n)

% (range)

PA isolates (n)

% (range)

PA isolates (n)

% (range)

Blinding present

I

15

21.1 (0.0-42.1)

61

47.8 (25.0-70.6)

NR

67

56.9 (42.9-77.8)

C

20

78.7 (75.0-82.4)

65

52.1 (27.7-76.5)

NR

75

25.3 (6.3-41.7)

[52,58]

[42,57]

[55,57,58]

Comparator drug class

β-lactam

I

108

39.9 (0.0-72.0)

95

52.7 (0.0-70.6)

81

14.6 (4.2-24.0)

137

31.3 (5.6-52.6)

C

107

84.7 (0.0-100.0)

110

56.3 (0.0-100.0)

76

2.5 (0.0-7.4)

131

20.1 (4.8-56.5)

[39,43,44,46,48,49,51,52,54,56]

[39,40,42,43,46,48,53,54,56]

[39,45,49]

[39,44,45,49,56,58]

Fluoro-quinolone

I

47

59.7 (41.2-72.0)

95

26.5 (25.0-29.4)

NR

83

41.6 (5.6-77.8)

C

47

73.6 (64.7-85.0)

110

45.5 (27.7-58.8)

NR

89

20.7 (6.3-41.7)

[44,46,47]

[46,47,57]

[44,47,55,57]

Nosocomial pneumonia

I

72

55.5 (41.2-72.0)

71

40.2 (25.0-50.0)

57

19.9 (4.2-24.0)

87

29.8 (5.6-52.6)

C

75

75.2 (64.7-85.0)

77

62.6 (50.0-76.5)

55

3.7 (0.0-7.4)

85

15.0 (6.3-35.7)

[39,44,46,47]

[39,42,46,47]

[39,45]

[39,44,45,47]

VAP subgroup

I

60.3 (41.2-72.0)

30.4 (25.0-35.7)

25

24.0 (NA)

55

30.4 (5.6-52.6)

C

78.7 (71.0-85.0)

57.5 (50.0-65.0)

28

0.0 (NA)

58

16.3 (6.3-35.7)

[39,44,47]

[39,46]

[39]

[39,44,47]

North America only

I

36

37.7 (0.0-72.0)

78

41.7 (25.0-70.6)

NR

71

44.4 (5.6-77.8)

C

37

74.9 (64.0-85.0)

82

54.3 (27.7-76.5)

NR

75

25.3 (6.3-41.7)

[44,46,52]

[42,46,57]

[44,55,57]


*Numbers in brackets represent corresponding references

PA: Pseudomonas aeruginosa, I: imipenem, C: comparator, NR: not reported, NA: not applicable, VAP: ventilator-associated pneumonia

Zilberberg et al. BMC Pulmonary Medicine 2010 10:45   doi:10.1186/1471-2466-10-45

Open Data